Biologics targeting interleukin (IL)-12, IL-23, and IL-17 may have valuable safety benefits among older adults with psoriatic disease, as a lower rate of serious infection was observed among these ...

Discover the signs of psoriatic arthritis, from joint pain and skin changes to nail damage and fatigue, plus the latest treatment options for this condition.

Medically reviewed by Stella Bard, MD Psoriatic arthritis (PsA) is a chronic (long-term) condition that includes symptoms of ...

Discover 5 insights about psoriatic arthritis from rheumatology experts, including pain management strategies, treatment ...

A rheumatologist discusses how her understanding of chronic pain in PsA has evolved—and how it affects her approach to ...

Visible signs of psoriatic arthritis appear months and even years before a person develops the full-blown inflammatory joint ...

Rheumatoid arthritis (RA) commonly causes joint pain, swelling, and inflammation. However, some people with RA will develop skin rashes. These can occur due to hives, vasculitis, and many other ...

Among a large cohort of young adults with psoriatic arthritis, 38.8% exhibited radiographic evidence of degenerative disc disease. Researchers in Canada conducted a retrospective cohort study to ...

Most of the time, psoriasis is the first symptom of psoriatic arthritis. It causes silvery-white skin lesions called plaques, which may appear on your scalp, elbows, knees, and lower back. Eventually, ...

US-based pharmaceutical company Johnson & Johnson (J&J) has reported positive results from a Phase IIIb trial of its monoclonal antibody Tremfya (guselkumab) for active psoriatic arthritis (PsA).

Patients with psoriatic arthritis (PsA) experienced longer diagnostic delays than matched patients with rheumatoid arthritis (RA). Patients with polyarticular PsA received less intensive disease ...

Long-term extension data show Tremfya (guselkumab) significantly reduced symptoms and inhibited structural joint damage progression in patients with active psoriatic arthritis. Findings from the Phase ...